Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis
Author Information
Author(s): Elyaman Wassim, Khoury Samia J., Scott David W., De Groot Anne S.
Primary Institution: Brigham and Women's Hospital and Harvard Medical School
Hypothesis
Can T regulatory cell epitopes (Tregitopes) be used as immunomodulating agents in the treatment of multiple sclerosis?
Conclusion
Tregitopes may serve as a promising therapy for multiple sclerosis by expanding regulatory T cells and inducing adaptive tolerance.
Supporting Evidence
- Tregitopes have been shown to expand Treg cells and induce adaptive Tregs.
- Immunoglobulin therapies have been associated with Treg expansion and IL-10 secretion.
- Tregitopes may provide a safer alternative to IVIg for treating autoimmune diseases.
Takeaway
Tregitopes are special pieces of proteins that can help the immune system calm down and stop attacking the body in diseases like multiple sclerosis.
Methodology
The study compares the effects of Tregitopes and intravenous immunoglobulin (IVIg) in the treatment of experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis.
Limitations
The study primarily focuses on experimental models and may not fully translate to human clinical outcomes.
Statistical Information
P-Value
p<0.002
Statistical Significance
p<0.002
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website